 |
0 Diseases |  |
643 Trials |
|
643 Trials |  |
26774 News |  |
| 12345678910111213...506507» |
- || cisplatin / Generic mfg.
Retrospective data, Review, Journal, Metastases: Neoadjuvant cisplatin-based chemotherapy in nonmetastatic muscle-invasive bladder cancer: A systematic review and pooled meta-analysis to determine the preferred regimen. (Pubmed Central) - Jun 22, 2024
Although rates of pathological complete response were not significantly different, pathological downstaging correlated with OS. ddMVAC should be preferred over gemcitabine/cisplatin for patients with muscle-invasive bladder cancer who can tolerate its greater toxicity.
- | Truqap (capivasertib) / Otsuka, AstraZeneca
Journal, Video: Toto-Cell: A new software to analyze cellular events during video-microscopy. (Pubmed Central) - Jun 21, 2024
In conclusion, our software is an important tool to facilitate the analysis of video-microscopy, in a quantifying and qualifying manner. It enables a higher accuracy when compared to manual calculations.
- | Polivy (polatuzumab vedotin-piiq) / Roche, Brukinsa (zanubrutinib) / BeiGene
New P2 trial: Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL (clinicaltrials.gov) - Jun 21, 2024
P2, N=20, Enrolling by invitation, Sponsor: The First Affiliated Hospital of Soochow University
- ||| Clinical guideline, Review, Journal: Effectiveness and safety of primary prophylaxis with G-CSF for patients with Ewing sarcomas: a systematic review for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology. (Pubmed Central) - Jun 21, 2024
This review indicated that G-CSF's efficacy as primary prophylaxis in Ewing sarcoma, except in children, is uncertain despite its common use. This review tentatively endorses intensified chemotherapy with G-CSF primary prophylaxis for Ewing sarcoma.
- | Journal: Subcutaneous Panniculitis-like T Cell Lymphoma Diagnosed with a Slowly Progressive Course: A Case Report. (Pubmed Central) - Jun 21, 2024
After 6 courses of CHOP, CT revealed no disease evidence. He remained in complete remission at 30 months of therapy.
- | AZD7648 / AstraZeneca
Journal: PRKDC Induces Chemoresistance in Osteosarcoma by Recruiting GDE2 to Stabilize GNAS and Activate AKT. (Pubmed Central) - Jun 20, 2024
The PRKDC inhibitor AZD7648 and DOX synergized and strongly suppressed the growth of osteosarcoma in mouse xenograft models and human organoids. In conclusion, the PRKDC-GDE2-GNAS-AKT regulatory axis suppresses DOX sensitivity and comprises targetable candidates for improving the efficacy of chemotherapy in osteosarcoma.
- || sorafenib / Generic mfg.
Clinical, Journal: Survival in Patients With Recurrent Intermediate-Stage Hepatocellular Carcinoma: Sorafenib Plus TACE vs TACE Alone Randomized Clinical Trial. (Pubmed Central) - Jun 20, 2024
P3
These findings suggest that combined treatment should be used for patients with recurrent intermediate-stage HCC after R0 hepatectomy with positive MVI. ClinicalTrials.gov Identifier: NCT04103398.
- | Rituxan (rituximab) / Roche
Journal, HEOR, Combination therapy: Quality of life assessment in diffuse large B-cell lymphoma (DLBCL) in REFLECT: a prospective, non-interventional, multicenter, German study, assessing Sandoz rituximab in combination with CHOP. (Pubmed Central) - Jun 20, 2024
ClinicalTrials.gov Identifier: NCT04103398. The objective of this analysis was to assess the impact of treatment with Sandoz rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) on HRQoL in treatment-na
- | ampicillin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Journal: Structural investigations and antibacterial, antifungal and anticancer studies on zinc salicylaldimine complexes. (Pubmed Central) - Jun 20, 2024
The objective of this analysis was to assess the impact of treatment with Sandoz rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) on HRQoL in treatment-na Among four bacteria, two ligands inhibited Staphylococcus aureus and Escherichia coli (9-10
- || Xtandi (enzalutamide capsule) / Pfizer, Astellas
P2 data, Journal: Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness". (Pubmed Central) - Jun 19, 2024
An iAR of at least 70% had a positive predictive value of 0.92 and a negative predictive value of 0.97 in predicting LAR-enriched TNBC according to RNA-based assays. Our data support future trials of AR blockade in early-stage LAR-enriched TNBC.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Outcome of serial cardiac evaluations during doxorubicin-based chemotherapy in small- to medium-sized dogs with multicentric lymphoma. (Pubmed Central) - Jun 19, 2024
The other echocardiographic results were not significantly different between each evaluation. In conclusion, our results showed no significant cardiotoxicity under echocardiogram and electrocardiogram in small- and medium-sized dogs without risk factors for DCM after four doses of doxorubicin in a 30-minute infusion method.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Arterial effects of anthracycline: structural and inflammatory assessments in non-human primates and lymphoma patients using 18 F-FDG positron emission tomography. (Pubmed Central) - Jun 19, 2024
Anthracyclines, such as doxorubicin, are important anti-cancer therapies but are associated with arterial injury...In a large animal model, anthracycline exposure was associated with aortic fibrosis. In patients with lymphoma, anthracycline exposure was not associated with aortic inflammation.Further research is required to elucidate the mechanisms of anthracycline-related vascular harm.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Apigenin's Modulation of Doxorubicin Efficacy in Breast Cancer. (Pubmed Central) - Jun 19, 2024
These results highlight the importance of understanding the nuanced interactions between apigenin and conventional chemotherapeutic drugs, as they could lead to more effective strategies for cancer treatment. This study underscores apigenin's potential as a modulator of cancer cell dynamics through mechanisms independent of its direct antioxidant effects, thereby contributing to the development of flavonoid-based adjunct therapies in cancer management.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Insights into Transfer of Supramolecular Doxorubicin/Congo Red Aggregates through Phospholipid Membranes. (Pubmed Central) - Jun 19, 2024
Both electrostatic and van der Waals interactions with lipids are important in this respect. The former promote the initial stages of the insertion process, the latter keep guest molecules inside the bilayer.
- | doxorubicin hydrochloride / Generic mfg., docetaxel / Generic mfg.
Journal: Baicalin and Baicalein Enhance Cytotoxicity, Proapoptotic Activity, and Genotoxicity of Doxorubicin and Docetaxel in MCF-7 Breast Cancer Cells. (Pubmed Central) - Jun 19, 2024
The results suggest that baicalin and baicalein might be promising complementary agents to improve the efficacy of doxorubicin and docetaxel anticancer activity. However, further research is needed to validate their safety and efficacy in clinical trials.
- | doxorubicin hydrochloride / Generic mfg.
Journal: The Application of Ultrasmall Gold Nanoparticles (2 nm) Functionalized with Doxorubicin in Three-Dimensional Normal and Glioblastoma Organoid Models of the Blood-Brain Barrier. (Pubmed Central) - Jun 19, 2024
Flow cytometry showed a reduction in glioblastoma cells after treatment with AuTio-Dox nanoparticles, as well as a higher uptake of these nanoparticles by GBM cells in the GBM model compared to astrocytes in the normal cell organoids. In summary, our results show that ultrasmall gold nanoparticles can serve as suitable carriers for the delivery of drugs into organoids to study BBB function.
- | Farydak (panobinostat) / Secura Bio, doxorubicin hydrochloride / Generic mfg.
Journal: Synergistic activities of Panobinostat and doxorubicin in soft tissue sarcomas. (Pubmed Central) - Jun 19, 2024
Furthermore, gene profile changes caused by LBH589 was studied by RNA-Sequencing analysis. Results showed LBH589 can exert effects on a group of target genes which can regulate potential biological functions especially in the cell cycle pathway.
- || Adcetris (brentuximab vedotin) / Takeda, Pfizer, Opdivo (nivolumab) / BMS, Matulane (procarbazine hydrochloride) / Leadiant Biosci
Review, Journal, Metastases: Treatment Strategies in Advanced-Stage Hodgkin Lymphoma. (Pubmed Central) - Jun 19, 2024
Lately, a significant advancement has been made by the integration of checkpoint inhibitors in the first-line treatment, with preliminary results demonstrating the superiority of anti-PD1 combined with chemotherapy (nivolumab-AVD) compared to the BV-AVD regimen. This review aims to analyze recently published studies whose findings could change the treatment practice in advanced-stage HL.
- | Victoza (liraglutide) / Novo Nordisk
Preclinical, Journal, IO biomarker: Liraglutide Pretreatment Does Not Improve Acute Doxorubicin-Induced Cardiotoxicity in Rats. (Pubmed Central) - Jun 19, 2024
In conclusion, doxorubicin-induced cardiotoxicity is accompanied by decreased Bcl-2 and phosphorylated NF?B and increased catalase activity and TLR-4 expression. Liraglutide failed to improve acute doxorubicin-induced cardiotoxicity in rats.
- | doxorubicin hydrochloride / Generic mfg.
Journal: The Protective Role of KANK1 in Podocyte Injury. (Pubmed Central) - Jun 19, 2024
In addition, KANK1-deficient human podocytes showed increased detachment and apoptosis following adriamycin exposure. These findings suggest that KANK1 may play a protective role in mitigating podocyte damage under pathological conditions.
- | NexoBrid (bromelain) / MediWound, Kaken Pharma, Teva
Journal: Optimization and mechanisms of proteolytic enzyme immobilization onto large-pore mesoporous silica nanoparticles: Enhanced tumor penetration. (Pubmed Central) - Jun 19, 2024
Conceivably, the DOX/CMSNs4.5-NH2-Coll nanodrug exhibited the most effective tumor therapy, with a tumor growth inhibition ratio of 86.1?%. The study provides excellent nanocarrier-enzyme complexes, and offers instructive theories for enhanced tumor penetration and therapy.
- | Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Journal: Empagliflozin attenuates doxorubicin-induced cardiotoxicity by inhibiting the JNK signaling pathway. (Pubmed Central) - Jun 19, 2024
The study provides excellent nanocarrier-enzyme complexes, and offers instructive theories for enhanced tumor penetration and therapy. Empagliflozin attenuated doxorubicin-induced apoptosis by inhibiting the phosphorylation of JNK and its downstream signaling pathways, including ROS and NAD+.
- | metformin / Generic mfg., doxorubicin hydrochloride / Generic mfg., naproxen / Generic mfg.
Journal: Design and synthesis of drug hydrogels containing carboxymethylcellulose with honeycomb structure and pH-sensitivity as drug delivery systems for adriamycin, metformin, and naproxen. (Pubmed Central) - Jun 19, 2024
The results of the survival studies for the manufactured systems showed a very good biocompatibility of the designed drug delivery systems for biological applications. By coating the surface of functionalized mesopores with CMC hydrogel, we were able to develop a pH-sensitive intelligent drug delivery system.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Light-driven rGO/Cu2?+?1O tubular nanomotor with active targeted drug delivery for combination treatment of cancer cells. (Pubmed Central) - Jun 18, 2024
bonding effect...Compared with non-powered nanocarrier and free DOX, light-propelled rGO/Cu2?+?1O nanomotors exhibit greater transmembrane transport efficiency and significant therapeutic efficacy. This proof-of-concept nanomotor design presents an innovative approach against tumor, enlarging the list of biomedical applications of light-driven micro/nanomotors to the superficial tissue treatment.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Defect-Rich Metastable MoS2 Promotes Macrophage Reprogramming in Breast Cancer: A Clinical Perspective. (Pubmed Central) - Jun 18, 2024
Moreover, the clinical feasibility of 1T2H-MoS2 is demonstrated via ex vivo therapeutic responses in human breast cancer samples. The apoptosis rate of cancer cells is 3.4 times greater than that of cells treated with chemotherapeutic drugs (i.e., doxorubicin).
- | doxorubicin hydrochloride / Generic mfg.
Journal: Loss of CELF2 promotes skin tumorigenesis and increases drug resistance. (Pubmed Central) - Jun 18, 2024
The apoptosis rate of cancer cells is 3.4 times greater than that of cells treated with chemotherapeutic drugs (i.e., doxorubicin). This study shows for the first time that CELF2 loss occurs during skin tumorigenesis and increases drug resistance in SCC cells, highlighting the possibility of targeting CELF2-regulated pathways in skin cancer prevention and therapies.
- || berubicin (RTA 744) / CNS Pharma, WPD Pharma
Trial primary completion date: A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - Jun 17, 2024
P2, N=210, Active, not recruiting, Sponsor: CNS Pharmaceuticals, Inc.
This study shows for the first time that CELF2 loss occurs during skin tumorigenesis and increases drug resistance in SCC cells, highlighting the possibility of targeting CELF2-regulated pathways in skin cancer prevention and therapies. Trial primary completion date: Sep 2024 --> Dec 2024
- | doxorubicin hydrochloride / Generic mfg.
Journal, Metastases: Platelet-Drug Conjugates Engineered via One-step Fusion Approach for Metastatic and Postoperative Cancer Treatment. (Pubmed Central) - Jun 17, 2024
We demonstrate doxorubicin (DOX)-encapsulated liposomes conjugated with interleukin-15 (IL-15) could fuse with platelets to achieve both cytoplasmic drug loading and surface cytokine modification with a loading efficiency of over 70% within minutes. Due to their inherent targeting ability to metastatic cancers and postoperative bleeding sites, the engineered platelets demonstrated a synergistic therapeutic effect to suppress lung metastasis and postoperative recurrence in mouse B16F10 melanoma tumor models.
- || doxorubicin hydrochloride / Generic mfg.
Review, Journal, Combination therapy: A comprehensive review on doxorubicin: mechanisms, toxicity, clinical trials, combination therapies and nanoformulations in breast cancer. (Pubmed Central) - Jun 17, 2024
It also discusses clinical trials evaluating doxorubicin-based regimens, the evolving landscape of combination therapies, and the potential of nanoformulations to optimize delivery and reduce systemic toxicity. The review also discusses the potential of liposomes, nanoparticles, and polymeric micelles to enhance drug accumulation within tumor tissues while sparing healthy organs.
- | Bosulif (bosutinib) / Pfizer, Iclusig (ponatinib) / Takeda, Otsuka, Brukinsa (zanubrutinib) / BeiGene
Journal: Integrative bioinformatics approach for identifying key genes and potential therapeutic targets in the concurrent manifestation of hypertrophic cardiomyopathy and pulmonary hypertension. (Pubmed Central) - Jun 17, 2024
The identification of six candidate drugs offers a hopeful vista for future therapeutic strategies targeting this complex cardiovascular interplay, marking a significant stride towards mitigating the compounded morbidity of HCM and PH. Future mechanistic and clinical studies are warranted for the investigation of this potential target and therapeutics.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Hairpin DNA-Based Nanomaterials for Tumor Targeting and Synergistic Therapy. (Pubmed Central) - Jun 17, 2024
We exploited nanoparticle coordination between ferric (Fe2+) ions and telomerase-targeting hairpin DNA structures to encapsulate doxorubicin (DOX) and fabricated Fe2+-DNA@DOX nanoparticles (BDDF NPs)...Harpin DNA-based nanoplatforms demonstrated prolonged blood circulation, tumor drug accumulation via telomerase-targeting, and synergistic therapy to improve antitumor drug efficacy. Our work sheds new light on nanomaterials for future synergistic chemotherapy.
- | Epidaza (chidamide) / Chipscreen
Journal: Molecular, biological characterization and drug sensitivity of chidamide-resistant MCF7 cells. (Pubmed Central) - Jun 17, 2024
The MCF7-CHI-R was established and the anti-ferroptosis pathway activation was involved in the resistance of MCF-CHI-R cells. Also, MCF7-CHI-R cells were resistant to GEM, ADM, DXT, nab-PTX and PTX.
- | Journal, Gene Signature, IO biomarker: A novel lactylation-related gene signature for effectively distinguishing and predicting the prognosis of ovarian cancer. (Pubmed Central) - Jun 17, 2024
There was good prognostic predictive performance for OC based on a lactylation-related signature. Our findings may offer new insights into the diagnosis and treatment of OC.
- | daunorubicin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Journal, IO biomarker: MicroRNA?223 overexpression suppresses protein kinase C ? expression in human leukemia stem cell?like KG?1a cells. (Pubmed Central) - Jun 17, 2024
In summary, the present study demonstrated that miR-223 could target and silence PKC? expression in KG-1a cells; however, the chemoresistance of KG-1a cells to anthracycline drugs may not be directly associated with the low expression of miR-223.
- | doxorubicin hydrochloride / Generic mfg.
Preclinical, Journal, IO biomarker: Bag1 protein loss sensitizes mouse embryonic fibroblasts to glutathione depletion. (Pubmed Central) - Jun 16, 2024
We found that the growth of mouse embryonic fibroblasts derived from Bag1?ex5-homo mice was attenuated by doxorubicin and a glutathione (GSH) synthesis inhibitor, buthionine sulfoximine...In addition, Bag1 might mitigate cellular hydrogen peroxide levels. Taken together, our results demonstrate that the loss of Bag1 did not affect mouse development and that Bag1 is involved in intracellular GSH homeostasis, namely redox homeostasis.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Mitochondrial transfer from Adipose stem cells to breast cancer cells drives multi-drug resistance. (Pubmed Central) - Jun 15, 2024
We provide a proof-of-concept of the occurrence of Mitochondrial Transfer (MT) from Adipose Stem Cells (ASCs) to BC models. Blocking MT from ASCs to BCCs could be a new effective therapeutic strategy for BC treatment.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Liguzinediol potentiates the metabolic remodeling by activating the AMPK/SIRT3 pathway and represses Caspase-3/GSDME-mediated pyroptosis to ameliorate cardiotoxicity. (Pubmed Central) - Jun 15, 2024
The findings of this study suggest that Lig effectively alleviates DOX-induced cardiotoxicity through the activation of the AMPK/SIRT3 pathway, thereby presenting itself as a natural product with therapeutic potential for preventing DOX-associated cardiotoxicity. This novel approach may pave the way for the development of alternative strategies in the clinical management of DOX-induced cardiac complications.
- | arsenic trioxide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Journal: Nano-fenretinide demonstrates remarkable activity in acute promyeloid leukemia cells. (Pubmed Central) - Jun 15, 2024
Nano-fenretinide was effective, albeit at slightly higher concentrations, also in doxorubicin-resistant HL60 cells, while a comparison with TK6 lymphoblasts indicated a lack of toxicity on normal cells. The results indicate that nano-fenretinide can be considered an alternative therapy to ATRA in acute promyelocytic leukemia when decreased efficacy, resistance or recurrence of disease emerge after protracted treatments with ATRA.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Disruption of DNA-PKcs-mediated cGAS retention on damaged chromatin potentiates DNA damage-inducing agent-induced anti-multiple myeloma activity. (Pubmed Central) - Jun 15, 2024
The results indicate that nano-fenretinide can be considered an alternative therapy to ATRA in acute promyelocytic leukemia when decreased efficacy, resistance or recurrence of disease emerge after protracted treatments with ATRA. Inhibition of DNA-PKcs could improve the efficacy of doxorubicin in treatment of MM by de-sequestrating cGAS in damaged chromatin.
- | doxorubicin hydrochloride / Generic mfg.
Journal: EYA4 reduces chemosensitivity of osteosarcoma to doxorubicin through DNA damage repair. (Pubmed Central) - Jun 15, 2024
Subsequently, our findings indicated that EYA4 could directly interact with histone H2AX to activate the DDR pathway. Taken together, our observations indicated that EYA4 may serve as a target molecule for reversing drug resistance in OS patients.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Self-Signal-Triggered Drug Delivery System for Tumor Therapy Using Cancer Cell Membrane-Coated Biocompatible Mn3O4 Nanocomposites. (Pubmed Central) - Jun 14, 2024
Subsequently, the chemotherapeutic drug doxorubicin (DOX) is encapsulated with Mn3O4 NPs, resulting in DOX/Mn3O4 NPs...In vitro toxicity tests show that Tf-HCM/DOX/Mn3O4 NC achieves significant anticancer activity against HeLa and BT20 cancer cells, with percentages of 76.46% and 71.36%, respectively. These results indicate the potential of Tf-HCM/DOX/Mn3O4 NC as an effective nanoplatform for chemo-photothermal therapy.
- | cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Journal: Determination of drug-drug interaction in breast cancer patients receiving doxorubicin and cyclophosphamide regimen. (Pubmed Central) - Jun 14, 2024
This study showed that the Drugs.com database detected more potential drug interactions between chemotherapy and nonchemotherapy than the Lexicomp and Micromedex databases. Comprehensive drug review, use of electronic health record systems, and collaboration between healthcare providers such as pharmacists and physicians may be necessary strategies to minimize potential drug-drug interactions and optimize cancer treatment in patients with breast cancer.
- | Journal: THE MANAGEMENT OF LYMPHOPROLIFERATIVE NEOPLASIA IN FOUR NORTHERN SEA OTTERS (ENHYDRA LUTRIS KENYONI). (Pubmed Central) - Jun 14, 2024
Survival time ranged from 81 to 409 days. Diagnosis, staging, and treatment with multiagent protocols is recommended for the management of lymphoma in sea otters.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Hyperactivation of p53 contributes to mitotic catastrophe in podocytes through regulation of the Wee1/CDK1/cyclin B1 axis. (Pubmed Central) - Jun 14, 2024
The current work aimed to study the role and mechanism of p53 in regulating the MC of podocytes using adriamycin (ADR)-induced nephropathy...Moreover, the inhibition of p53 blocked the progression of MC in podocytes in ADR nephropathy mice through the regulation of the Wee1/CDK1/cyclin B1 axis. Our findings confirm that p53 contributes to MC in podocytes through regulation of the Wee1/CDK1/Cyclin B1 axis, which may represent a novel mechanism underlying podocyte injury and loss during the progression of chronic kidney disorder.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Thermal-responsive ?-cyclodextrin-based magnetic hydrogel as a de novo nanomedicine for chemo/hyperthermia treatment of cancerous cells. (Pubmed Central) - Jun 14, 2024
Our findings confirm that p53 contributes to MC in podocytes through regulation of the Wee1/CDK1/Cyclin B1 axis, which may represent a novel mechanism underlying podocyte injury and loss during the progression of chronic kidney disorder. The hydrogel was physically loaded with an anticancer agent, doxorubicin hydrochloride (Dox)...In addition, flow cytometry analyses showed considerable cellular uptake of Dox in the cells treated with ?-CD-g-PNIPAAm/Fe3O4-Dox (?70
- | doxorubicin hydrochloride / Generic mfg.
Journal, IO biomarker: Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms. (Pubmed Central) - Jun 14, 2024
Mechanistically, GHRP-6 proved to sustain cellular antioxidant defense, upregulate prosurvival gene Bcl-2, and preserve cardiomyocyte mitochondrial integrity. These evidences contribute to pave potential avenues for the clinical use of GHRP-6 in Dox-treated subjects.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Self-propelled enzyme-controlled IR-mesoporous silica Janus nanomotor for smart delivery. (Pubmed Central) - Jun 13, 2024
Gluconic acid leads to a pH reduction at the nanomachine microenvironment causing the disruption of the gating mechanism with the subsequent cargo release. This work demonstrates that enzyme-mediated self-propulsion improved release efficiency being this nanomotor successfully employed for the smart release of Doxorubicin in HeLa cancer cells.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Efficient delivery of anticancer drugs using functionalized-Ag-decorated Fe3O4@SiO2 nanocarrier with folic acid and ?-cyclodextrin. (Pubmed Central) - Jun 13, 2024
In this work, the fabrication of functionalized-Ag-decorated Fe3O4@SiO2 (Fe3O4@SiO2-Ag) nanocarriers with folic acid (FA) and ?-cyclodextrin (BCD) exhibit a remarkable capacity for delivering two types of anticancer drugs, i.e., doxorubicin (DOX) and epirubicin (EPI), into cancer cells...Furthermore, the drug-loaded functionalized-nanocarrier showed cytotoxic effects on SK-MEL-2 cells, as demonstrated by an in vitro MTT assay. This suggests that the as-prepared functionalized-nanoparticles have promise as a carrier for the efficient anticancer drugs.
- | donepezil / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Preclinical, Journal: Donepezil Ameliorates Gut Barrier Disruption in Doxorubicin-treated Rats. (Pubmed Central) - Jun 13, 2024
Doxorubicin impaired the autonomic balance and the gut barrier, and induced gut dysbiosis, resulting in gut toxicity. Donepezil partially improved the doxorubicin-induced gut toxicity through balancing the autonomic disturbance.
- | Herceptin (trastuzumab) / Roche
Journal, Combination therapy, Cancer stem: Liposome-enabled bufalin and doxorubicin combination therapy for trastuzumab-resistant breast cancer with a focus on cancer stem cells. (Pubmed Central) - Jun 13, 2024
The cytotoxicity against the bulk cancer cells was also enhanced by the liposomal combination than either formulation alone in both cell lines (p?<?0.001). The liposomal bufalin and doxorubicin combination therapy may effectively target both BCSCs and bulk cancer cells for a better outcome in trastuzumab-resistant HER2 breast cancer.